Circio Holding ASA

AGM Information • Dec 19, 2025

Circio Holding ASA Notice of extraordinary general meeting on 12 January 2026

Circio Holding ASA Notice of extraordinary general meeting on 12 January 2026

Oslo, Norway, 19 December 2025 -- Circio Holding ASA (OSE: CRNA, a

biotechnology company developing novel circular RNA expression technology for

gene and cell therapy, hereby calls for an extraordinary general meeting (the

"EGM") to be held on 12 January 2026 to resolve inter alia the proposed 88%

secured rights issue of up to NOK 50 million (the "Rights Issue") as announced

on 8 December 2025.

The EGM will be held on Monday 12 January 2026 at 10:00 hours (CET) as a

physical meeting at the Company's offices at Tordenskiolds gate 2 (c/o Mesh),

0160 Oslo, Norway.

The Rights Issue will be priced at NOK 1.00 per share and has strong support

from Circio s main shareholders, who have presubscribed for NOK 24.2 million

(48.4%) of the Rights Issue. An additional underwriting commitment of NOK 20

million (40%) brings the total secured transaction level to 88.4% of the NOK

50 million.

Going forward, the net proceeds from the Rights Issue will serve as Circio's

main source of funding. Following the announcement of the Rights Issue, the

financing facility provided by Atlas Capital Markets LLC ("Atlas") has been

closed. No convertible bonds remain outstanding, and Atlas no longer holds any

shares in Circio.

The Rights Issue is expected to provide Circio with the necessary capital to

fund its operations for approximately twelve months. This will enable Circio

to deliver on several important pre-clinical circVec platform milestones and

business development activities, including the recently announced feasibility

study with a major global pharma company. The additional 1:1 warrant coverage

per share subscribed in the Rights Issue will provide Circio with an

opportunity to raise additional funds in June 2026, which is anticipated to

prolong the cash runway well into 2027.

To carry out the Rights Issue, the board of directors has proposed that the

EGM resolves several matters relating to the Rights Issue, including:

i. share capital increases,

ii. issuance of warrants,

iii.issuance of shares and warrants to the pre-subscribers and potentially to

the underwriter in the Rights Issue to settle the commission, and

iv. to ensure that the Pre-subscribers are allocated offer shares and warrants

for their full pre-subscription amount in the Rights Issue, the board of

directors proposes a private placement to increase the Company's share

capital by issuing new shares to the pre-subscribers and warrants to the

extent that the pre-subscribers are not allocated offer shares for their

full pre-subscription amount.

In addition, the board of directors proposes that the EGM renews the

authorization to increase the Company's share capital by 40%, which is

important to be able to take advantage of the opportunity to complete equity

issues when market conditions are considered attractive.

Also, the board of directors proposes that the EGM renews the authorization to

increase the Company's share capital in connection with share incentive option

program, which is an important element in the recruitment and retention of key

employees.

The notice and agenda of the EGM are attached hereto including further

information on advance voting, power of attorney and physical participation.

The notice is also made available on the Company's webpage www.circio.com

(https://www.circio.com/) under the heading "Investors".

This information is subject to disclosure under the Norwegian Securities Act

section 5-12 and the requirements of Oslo Børs' Continuing Obligations.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Email: erik.wiklund@circio.com

Lubor Gaal, CFO

Phone: +34 683 34 3811

Email: lubor.gaal@circio.com

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA

expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression

technology for next generation RNA, DNA and viral therapeutics. The

proprietary circVec platform is based on a modular genetic construct designed

for efficient biogenesis of multifunctional circRNA inside target cells. The

circVec platform has applications in multiple therapeutic settings, including

genetic medicine, cell therapy and chronic disease. It has demonstrated

75-fold increased RNA half-life and up to 40-fold enhanced protein expression

vs. conventional mRNA-based viral and non-viral vector systems, with the

potential to become a new gold-standard gene expression technology. The

circVec R&D activities are being conducted by the wholly owned subsidiary

Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology

program, TG01, through cost-efficient external academic and industry

collaborations. TG01 targets RAS-mutated cancers and is being tested in two

clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine

adjuvanted by STIMULON QS-21 licensed from Agenus Inc.